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Parkinson's disease (PD) is a progressive neurodegenerative disease that impairs people's lives tremendously. The
development of innovative treatment modalities for PD is a significant unmet medical need. The critical function
of glucagon-like peptide-1 (GLP-1) in neurodegenerative diseases has raised impetus in investigating the repo
sitioning of a dipeptidyl peptidase IV inhibitor, alogliptin (ALO), as an effective treatment for PD. As a result, the
focus of this research was to assess the effect of ALO in a rat rotenone (ROT) model of PD. For 21 days, ROT (1.5
mg/kg) was delivered subcutaneously every other day. ALO (30 mg/kg/day), delivered by gavage for 21 days,
recovered motor performance and improved motor coordination in the open-field and rotarod testing. These
impacts were highlighted by restoring striatal dopamine content and correcting histological changes that
occurred concurrently. The ALO molecular signaling was determined by increasing the quantity of GLP-1 and the
protein expression of its downstream signaling pathway, pT172-AMPK/SIRT1/PGC-1α. Furthermore, it curbed
neuroinflammation via hampering HMGB1/TLR4/NLRP3 inflammasome activation and conquered striatal
microglia activation. Pre-administration of dorsomorphin reversed the neuroprotective effects. In conclusion, the
promising neuroprotective effect of ALO highlights the repositioning of ALO as a prospective revolutionary
candidate for combating PD.

1. Introduction
Parkinson's disease (PD) is a neurodegenerative complication that
most commonly impacts elderly persons [1]. It is caused by dopami
nergic neurons degenerating predominantly in the substantia nigra pars
compacta (SNpc), followed by dopamine (DA) shortage in the striatum
[2]. The pathophysiology of PD is complex, with multiple connected
mechanisms being implicated, including inflammation [3], mitochon
drial malfunction [4], apoptosis [5], disturbed redox status [6], and
protein misfolding [7]. This complicates the task of identifying a suitable
chemical capable of modulating this complicated network. Likewise, the
hunt for viable alternatives or adjuncts to the standard gold treatment
for PD, L-dopa, continues, as the drug does not address the disorder's
degenerative nature and produces motor problems including wearingoff and dyskinesia after prolonged use [8].
The NLRP3 inflammasome (nucleotide-binding and oligomerization
domain (NOD)-like receptor pyrin domain-containing 3) is a multi-

protein complex that consists of an apoptosis-associated speck-like
protein like NLRP3, caspase recruitment domain (ASC), and procaspase1. It not only roles as a crucial regulator of innate immunity but also has
a significant function in inflammatory conditions [9]. Recent data in
dicates that the NLRP3 inflammasome is involved in the pathogenesis of
neurodegenerative disorders like PD [10]. Inevitably, stimulation of the
NLRP3 inflammasome activates caspase-1, catalyzing the conversion of
dormant versions of interleukin-1 and interleukin-18 (pro-IL-1 and proIL-18) to mature IL-18 and IL-1 [11,12]. Following that, these in
terleukins activate downstream cytokines and specific chemokine re
ceptors, resulting in neuroinflammation [13]. The high-mobility group
box 1 (HMGB1) proteins, fusion proteins, and heat shock proteins are all
examples of damage-associated molecular patterns (DAMPs), that could
be programmed to emerge from specific cells throughout inflammation
activating toll-like receptors (TLRs) [14]. Stimulation of TLR can result
in amplified NLRP3 transcription and consequent inflammation [15]. In
particular, HMGB1 has been implicated in neuroinflammation [16].
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Sirtuin 1 (SIRT1) is required to properly control cellular inflamma
tion [17]. Interestingly, the main inflammation regulator, NF-κB, was
discovered to be a substrate of SIRT1 [18]. The experimental study of Li
et al. [19] revealed that NLRP3 inflammasome is regulated by SIRT1.
However, such a relation is poorly ascribed in neuroinflammation
associated with PD. Being a histone deacetylase, SIRT1 is required for
autophagy induction during deacetylating autophagy-related proteins
[20]; however, SIRT1 mediators are employed to increase autophagy in
PD rat models and prevent the formation of α-synuclein aggregates [21].
Autophagy, one of nature's destructive processes, is thought to be
impaired in PD [22]; yet enhanced removal of misfolded proteins or
degraded mitochondria using autophagy promoters possess neuro
protective influence in models of PD [23,24].
Interestingly, SIRT1 and AMPK (AMP-activated protein kinase) are
critical regulators of mitochondrial biogenesis. They are identified as
gatekeepers of peroxisome proliferator-activated receptor gamma
(PPAR-γ) and coactivator-1α (PGC-1α), the master regulators of mito
chondrial biogenesis [25]. The PGC-1α is expressed primarily in tissues
that produce oxidative energy, like the brain [26]. In a finely calibrated
network, AMPK and SIRT1 positively control one another's activity [27].
Previous research indicated that the AMPK/SIRT1 mode of action affects
the avoiding and developing CNS inflammatory disorders [28,29].
Gliptins are oral antidiabetic medications that are both effective and
well-tolerated when used to treat non-insulin-dependent diabetes mel
litus and its complications. They raise incretin concentration by
decreasing dipeptidyl peptidase IV activity (DPP-4), a gut hormone
involved in the glucagon-like peptide-1 decomposition (GLP-1), then
raising both glucagon and insulin release [30]. Not only does GLP-1
produced in the stomach cross the blood-brain barrier, but it is also
produced in the brain and functions on GLP-1 receptor, providing antiinflammatory and antiapoptotic effects in the CNS, hence preventing
neurodegeneration [31,32]. Gliptins have been proven to reverse neu
rodegeneration in cell cultures and experimental animals [33,34]. The
antiparkinsonian impacts of several DPP-4 inhibitors, like vildagliptin
[35] and sitagliptin [36] were previously verified. Moreover, saxagliptin
was associated with antiapoptotic, antioxidant, and neurorestorative
effects [37]. A previous in vitro study indicated that linagliptin activated
AMPK and its downstream target SIRT1, thereby protecting neurons
against amyloid-induced neuronal cell death [33]. However, it has to be
determined if the antiparkinsonian effects of gliptins are due to activa
tion of AMPK/SIRT1 signaling and reduction of neuroinflammation via
modulation of NLRP3 inflammasome activity.
Alogliptin (ALO) is a highly specific and effective DPP-4 inhibitor
used clinically to treat type II diabetes mellitus. The ALO revealed po
tential neuroprotective benefits in rats following brain ischemia/reper
fusion [38] and decreased neuroinflammation in the hippocampi of
diabetic rats [39]. The current research examined the prospective neu
roprotective benefits of ALO in the rotenone (ROT)-induced PD model in
rats, with a particular emphasis on dopaminergic neuron integrity
maintenance via AMPK/SIRT1 signaling and NLRP3 inflammasome
regulation. This work opens new horizons for drug repositioning of
gliptins in PD. In this study, ROT was used to induce PD in rats. As a
selective inhibitor of complex I of the electron transport chain, it inhibits
ATP generation, hence impairing mitochondrial functional respiration.
Additionally, this neurotoxin generates an excessive amount of reactive
oxygen species (ROS), resulting in extreme oxidative damage to lipids,
DNA, and proteins along with apoptosis induction in dopaminergic
neurons [40], which results in behavioral signs similar to PD, such as
impaired movement, curved posture, and rigidity [41].

rats were housed at the animal shelter at Cairo University's Faculty of
Pharmacy for two weeks to acclimate to the laboratory conditions. Rats
were kept in a climate-controlled setting with a room temperature of 22
± 2 ◦ C, relative humidity of 60 ± 10%, and a 12/12 h light/dark cycle
(lights on from 07.00 to 19.00). A standard chow meal and unlimited
amounts of water were provided. The study adhered to the National
Institutes of Health's Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85–23, revised 2011) and was authorized through
Ethics Committee of Faculty of Pharmacy, Cairo University, Egypt
(Permit number: PT 2975) and the Faculty of Pharmacy, British Uni
versity, Egypt (Permit number: EX-2110).
2.2. Drugs and chemicals
Alogliptin was received from the Rameda Pharmaceutical Company
in Cairo, Egypt, and dorsomorphin (DOR) and ROT from the SigmaAldrich Company in St. Louis, Missouri, USA. Fresh solutions for drugs
and chemicals were prepared prior to use. Rest of chemicals used in this
investigation were of the purest and highest analytical quality.
2.3. Experimental design
Sixty-four rats were assigned randomly to 4 groups of 16 rats each:
First group: Every day, rats got 11 subcutaneous injections of 10%
dimethyl sulfoxide (DMSO, 0.2 ml/kg) on alternate days over a 21-day
period and functioned as a normal control group.
Second groups: Rats were given 11 subcutaneous injections of ROT at
a dose of 1.5 mg/kg dissolved in 10% DMSO on alternate days over a 21day period [42].
Third group: Rats were administered with ROT in the previously
described manner. In addition, ALO was dissolved in 1% tween 80 and
administered orally at dose a of 30 mg/kg every day [38]; 1 h prior to
ROT injection on days when Rot is administered.
Fourth group: rats received ROT and ALO as previously described.
However, rats received ALO together with DOR that was dissolved in
10% DMSO and was intravenously injected at a dose of 25 μg/rat every
day [43].
The motor functions of the animals were assessed 24 h following the
final ROT injection utilizing open field and rotarod testing. Then, rats in
each group were randomly separated into three subsets and sacrificed
under thiopental sodium anesthesia by dissection. Brains were dissected
and rinsed in ice-cold saline. Brains were fixed in 10% formalin/saline
for histological inspection and immunohistochemical investigation in
the first batch (n = 3). In the second batch (n = 7), the two striata were
separated rapidly, frozen in liquid nitrogen, and stored at − 80 ◦ C for the
estimation of DA, GLP-1, AMPK, SIRT1, PGC-1α, HMGB1, mitochondrial
transcription factor A (TFAM). In the third batch (n = 6), striata from 3
rats were separated, frozen in liquid nitrogen, and preserved at − 80 ◦ C
for later western blotting of caspase-1 and NLRP3. Striata from the other
3 rats were utilized to measure toll-like receptor 4 (TLR4) using the
quantitative real-time PCR approach.
2.4. Bodyweight change and survival rate
Each rat was weighed on the first and last days of testing, and the
difference in body weight was computed as the difference between the
last and first days' weights.
Additionally, the survival of rats in each group was monitored, and
the percent survival was determined using the following equation:

2. Materials and methods

%survival =

2.1. Animals

Number of rats in last day
× 100
Number of rats in first day

2.5. Behavioral analysis

We obtained 200–250 g adult male Wistar rats from the Nile Com
pany for Chemical and Pharmaceuticals Industries in Cairo, Egypt. The

Behavioral evaluation was performed during the light phase in a
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sound-isolated laboratory. Rats were initially screened using the open
field test then the rotarod test, with a 2-h rest time between sessions
[44].

alteration in protein relative to control animals.
2.6.3. Quantitative real-time RT-PCR analysis
The GeneJET RNA Purification Kit was used to collect RNA (Thermo
Fisher Scientific, MA, USA), as per the manufacturer's instructions.
Reverse RNA transcription (1 g) was performed according to the in
structions from the generating company utilizing a High-Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientific, MA, USA). The
Maxima SYBR Green qPCR master mix (Thermo Fisher Scientific, MA,
USA) was employed for real-time PCR amplification. Quantitative realtime PCR was done in triplicate on each sample using the SYBR Green
technique on the StepOne™ Real-Time PCR System (Software version
3.1, Applied Biosystem, USA). As a negative control, diethylpyrocar
bonate (DEPC) treated water was used as a no template control (NTC).
Primer sequences for the relevant genes were constructed using the IDT
PrimerQuest Primer Design Tool. The accompanying primers were used
(oligonucleotide sequences for sense and antisense primers are indicated
in parentheses): TLR4: 5′ -CATGACATCCCTTATTCAACCAAG-3′ and 5′ GCCATGCCTTGTCTTCAATTG-3′ ,
and
GAPDH:
5′ -CAGTGC
CAGCCTCGTCTCAT − 3′ and 5′ -CAAGAGAAGGCAGCCCTGGT-3′ . The
expression levels of the target gene were normalized to endogenous
corresponding GAPDH threshold cycle (CT) values. Normalization was
carried out using the 2-∆∆Ct comparative method, and the outcomes
were shown in arbitrary units [47].

2.5.1. Open field test
The open field instrument was utilized to examine rats' exploratory
behavior and general performances. It was a wooden box 80 × 80 cm
square with 40 cm high red borders. White lines split the black smooth
polished floor into sixteen equal squares. Every rat was positioned softly
in the center portion of the open field and permitted to roam freely for 3
min. The distance traveled, mean speed, time spent immobile, ambu
lation frequency, and rearing frequency were all recorded with a video
camera set on the box's top and analyzed with ANY-Maze video moni
toring software (Stoelting Co, USA). Following the testing of each rat,
the floor and walls were thoroughly cleaned and dried with 20% ethanol
to reduce scent cue bias [45].
2.5.2. Rotarod test
Rats' motor coordination and balance were evaluated utilizing an
automated 5-lane rotarod apparatus (Model 47,750, Ugo Basile, Italy),
in which rats were put in the opposite direction of a persistent spinning
rod (20 rpm). Before the trial, all rats were trained twice daily for three
respective days at a set pace of 4 rpm for 3 min per session. Rats that
remained on the rod for the longest period were chosen to conduct the
experiment. On the test day, the rod's fall-off time was measured for 3
min [46].

2.7. Histopathologic examination
Brain samples were rinsed and then fixed for 72 h in 10% formalin/
saline. Trimmed and treated in progressive grades of ethanol, samples
were then cleaned in xylene before being infiltrated and embedded in
paraffin. In four distinct samples, four micron-thick sagittal brain slices
were cut to examine the SNpc and striatal areas. Hematoxylin and eosin
(H & E) staining of tissue sections was followed by examination under a
light microscope (Leica Microsystems GmbH, Wetzlar, Germany) [48].

2.6. Biochemical measurements
2.6.1. Enzyme-linked immunosorbent assay
The relevant parameters were measured in striatal tissues as per the
generators' instructions by rat-specific enzyme-linked immunosorbent
assay (ELISA) kits: DA, IL-1β, and p-AMPK from MyBioSource (Catalog
No: MBS725908, MBS825017, and MBS7230575, respectively, CA,
USA), GLP-1 from Sunlong Biotech Co. (Catalog No: SL0304Ra, Zhe
jiang, China), SIRT1 from Cloud-Clone Corp. (Catalog No: SEE912Ra,
TX, USA), besides PGC-1α, TFAM and HMGB1 from Cusabio Technology
LLC (Catalog No: CSB-EL018425RA, CSB-EL023413RA, and CSBE08224r, respectively, Wuhan, China).

2.8. Immunohistochemical examination
Anti-tyrosine hydroxylase (TH) antibody was incubated with
paraffin-embedded brain sections (Catalog No: ab112, Abcam, Cam
bridge, UK, 1:200) and anti-Iba1 (ionized calcium-binding adaptor
molecule 1) antibody (Catalog No: ab108539, Abcam, Cambridge, UK,
1:100) overnight at 4 ◦ C. After washing with PBS, tissue slices were
incubated for 20 min with Envision Detection System Peroxidase/DAB,
Rabbit/Mouse (Dako Real TM Envision TM Detection System Peroxi
dase/DAB+, Rabbit/Mouse, Dako, Glostrup, Denmark); A 15-min in
cubation with 3,3′ -diaminobenzidine tetrahydrochloride (DAB
Substrate Kit, Vector Laboratories Inc., CA, USA) was used to visualize
the reaction. After counterstaining with hematoxylin, dehydrating, and
clearing in xylene, slices were covered, slid, and observed under a light
microscope. The area percentage of TH immunoexpression in six nonoverlapping fields 304*180 μm per tissue section (at least 2 step
anatomical sections per sample were analyzed) was obtained at fixed
thresholds of true positive reactions as defined by the histologist and
quantified using a histological analysis module (Leica Microsystems
GmbH, Wetzlar, Germany). Similarly, Iba1 levels in striatal tissue sec
tions were measured by counting Iba1-positive microglial cells. To
eliminate bias, all histopathological results were considered by a qual
ified investigator who was blinded to the samples' identity.

2.6.2. Western blot analysis
Homogenization of striatal tissues was performed in RIPA buffer
enriched with Halt Protease and Phosphatase Inhibitor Cocktail
(Thermo Fisher Scientific, IL, USA). At 4 ◦ C, the homogenate was
centrifuged for 10 min at 13,000 rpm. The Pierce BCA protein assay kit
(Thermo Fisher Scientific, IL, USA) was utilized to assess the protein
concentrations. One hundred microgram of protein extracts were heatdenatured for 10 min at 70 ◦ C in NuPAGE LDS Sample Buffer (Thermo
Fisher Scientific, IL, USA) enriched with 2% beta-mercaptoethanol,
separated on a 10% SDS-PAGE polyacrylamide gel, and electroblotted
onto a nitrocellulose membrane. The membrane was blocked for 1 h at
room temperature with gentle shaking with 5% nonfat dry milk in Trisbuffered saline with Tween 20 (TBST). The succeeding antibodies were
utilized: anti-b-actin (NB600-503SS, Novus Biologicals, USA, 42 kDa, 1:
1000 dilution), anti-caspase 1 antibody (NBP1–45433, Novus Bi
ologicals, USA, 45 kDa, 2 g/Primary antibodies were diluted in blocking
solution and incubated overnight at 4 ◦ C with the blots. The blots were
washed three times with TBST for 5 min each and then coated with a
secondary antibody conjugated to horseradish peroxidase (NB7160,
Novus Biologicals, USA, 1: 24000 dilution) for 1 h at room temperature
with moderate shaking. ChemiDoc MP Imaging System was used to
observe the blots after being incubated with enhanced chem
iluminescence (Clarity Western ECL, Bio-Rad, CA, USA) (Bio-Rad, CA,
USA). The bands' intensities were assessed by the ImageJ program (NIH,
MD, USA). The immunoblot results (Supplementary Figs. 1 & 2) were
normalized to the corresponding -actin values and expressed as fold

2.9. Statistical analysis
Data are presented as means ± S.D. Data were analyzed using oneway ANOVA followed by the Tukey–Kramer multiple comparisons
test, except for the rearing frequency, which were analyzed using
Kruskal–Wallis ANOVA followed by Dunn's multiple comparisons test.
GraphPad Prism version 8 was utilized (GraphPad Software Inc., San
3
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Diego, CA, USA) for data analysis. All statistical studies have a level of
significance of less than 0.05.

numerous figures of angular deteriorated and pyknotic neurons. ALOtreated rats showed significantly higher records of apparent intact,
well-protected neurons in striatum and SNpc with intact subcellular
details and minimal records of neuronal damage, accompanied with
mildly congested blood vessels as well as mild reactive glial cell in
filtrates. Whereas rats given DOR exhibited the same neuronal patterns
as model samples but with significantly higher levels of necrotic and
impaired neuronal recordings (Fig. 2).
As illustrated in Fig. 3, the ROT group had a significant loss of TH in
the SNpc, as indicated by a decrease in TH immunoreactivity (67.03%, F
(3,8) = 101.3, P < 0.0001) as contrasted to the control rats. Such
derangement was reverted in ALO-treated rats, which exhibited an in
crease by 1.42-fold (P < 0.0001) in TH immunoreactivity compared to
the ROT group. DOR pretreatment prevented this recovery, reaching
only 74.77% (P < 0.0001) of TH immunoreactivity of the ALO group.
It is reported that striatal microglia are activated in ROT exposed rats
[49]. To evaluate whether ALO could counteract such activation, striatal
immunostaining of the microglial activation marker Iba1 was used
(Fig. 4). ROT rats showed an increased number of Iba1-positive cells
(5.69-fold, F (3,8) = 162.3, P < 0.0001) contrasted with controlling rats,
an impact that was considerably mitigated by ALO treatment (33.78%,
P < 0.0001) compared to the ROT group. DOR pretreatment halted the
decline of Iba1 immunoreactivity, reaching 2.92-fold (P < 0.0001)
compared to the ALO group.
AMPK/SIRT1 pathway is documented as one of the molecular
mechanisms for GLP-1's effects as well as a regulator of mitochondrial
biogenesis [50,51]. As shown in Fig. 5, ROT rats exhibited a marked
decrease in striatal contents of pT172-AMPK (48.69%, F (3,20) = 19.11,
P < 0.0001), SIRT1 (69.06%, F (3,20) = 15.25, P = 0.009), PGC-1α
(49.86%, F (3,22) = 18.84, P < 0.0001), and TFAM (70.12%, F (3,16) =
114.7, P < 0.0001). Both AMPK and SIRT1 were normalized with ALO
treatment, whereas PGC-1α and TFAM were markedly boosted (1.41-(P
= 0.023) and 1.29-fold (P < 0.0001), respectively). DOR administration
prevented ALO's amendment of those biomarkers, reaching 55.27% (P
= 0.004), 51.09% (P = 0.0001), 79.82% (P = 0.162), and 84.36% (P <
0.0001), respectively, compared to ALO rats.
Toll-like receptor stimulation via DAMPs might act as an activation
signal for the inflammasome system [49]. As illustrated in Fig. 6, ROT
administration boosted striatal HMGB1 levels (1.96-fold, F (3,16) =
219.8, P < 0.0001) as well as TLR4 expression (10.96-fold, F (3,20) =
8103, P < 0.0001). This was paralleled by an increase of the inflam
masome components, namely NLRP3 (20.31-fold, F (3,20) = 31.16, P <
0.0001), cleaved caspase-1 (8.95-fold, F (3,20) = 52.31, P < 0.0001),
and IL-1β (2.33-fold, F (3,24) = 26.33, P < 0.0001). ALO treatment
impeded the inflammatory surge induced by ROT through decreased
striatal HMGB1 (62.73%, P < 0.0001) as well as TLR4 expression
(23.51%, P < 0.0001). A concomitant decrease in inflammasome acti
vation was evidenced by a reduction of NLRP3 (16.22%, P < 0.0001),
cleaved caspase 1 (33.08%, P < 0.0001), and IL-1β (48.78%, P <
0.0001). This recovery, however, was dampened in rats pretreated with
DOR.

3. Results
As shown in Table 1, ROT administration reduced survival (66.6%)
which was largely mitigated by ALO treatment. Additionally, ROT
caused a considerable decrease in body weight that was not worsened by
ALO or the co-administration of ALO with the AMPK inhibitor DOR.
Moreover, ROT striatal toxicity was manifested as reducing both striatal
DA (64.83%, F (3,23) = 13.9, P < 0.0001) and GLP-1 (41.56%, F (3,23)
= 121.9, P < 0.0001) compared to control rats. ALO treatment afforded
a significant increase in both biomarkers, reaching 126.61% (P = 0.04)
and 334.38% (P < 0.0001), respectively, compared to the ROT group. It
is noteworthy that pre-administration of DOR markedly abated ALO's
beneficial effects on mortality as well as striatal DA depletion.
Locomotor deficits are a hallmark of ROT striatal toxicity. As illus
trated in Fig. 1, rats treated with ROT demonstrated severe impairments
in motor function in both the open field and rotarod tests. The latter
manifested as a decline in the distance covered (52.91%, F (3,43) =
13.7, P < 0.0001), mean speed (52.88%, F (3,43) = 14.98, P < 0.0001),
rearing frequency (26.81%), and rotarod fall-off latency (39.88%, F
(3.43) = 15.41, P < 0.0001) coupled with an elevation in immobility
time (1.64-fold, F (3,43) = 13.84, P = 0.0004) contrasted with con
trolling group. Contrariwise, the ALO-treated group showed a marked
recovery of motor performance manifested as an increase in distance
covered, mean speed, rearing frequency, and fall off latency (1.54-(P =
0.026), 1.57-(P = 0.016), 2.90- and 1.86-fold (P = 0.013), respectively)
together with reduced immobility time (72.62%, P = 0.026) as
compared to ROT group. These improvements were significantly abated
by DOR pre-administration.
The motor impairment instigated by ROT corroborated with histo
pathological findings. The normal control group had typical striatal
histological characteristics, such as an abundance of apparent intact big
and small neurons with intact subcellular details, intact myelinated fi
bers, and sparse glial cell infiltrates and vasculatures. Along with normal
histological structures of the SNpc, which include numerous visible
intact neurons with big vesicular, spherical nuclei and granular baso
philic cytoplasm, and a normal surrounding intercellular brain matrix.
ROT rats showed moderate records of focal neuronal damage with
interspersed shrunken, degenerated, and pyknotic neurons in-between
intact cells accompanied with moderate glial cells infiltrate. In addi
tion to significant neuronal degeneration and death, the SNpc contains
Table 1
Effect of ALO administration on survival, weight change, striatal dopamine, and
GLP-1 levels in rotenone-injected rats.
Control

ROT

ROT + ALO

ROT + ALO
+ DOR

66.66
223.7 ± 8.3

80
224.1 ± 7.3

66.66
225.4 ± 6.8

197 ± 9.6*

Striatal DA (ng/g
tissue)
Striatal GLP-1 (ng/
g tissue)

48.46 ±
9.22
0.77 ±
0.12

205.1 ±
10.3*
− 19 ±
9.20*
39.78 ±
2.27*,#
1.07 ±
0.05*,#

202.4 ± 7.9*

Weight change (g)

100
225.2 ±
13.2
275.2 ±
16.9
50 ± 8.86

Survival (%)
Initial weight (g)
Final weight (g)

− 26.67 ±
12.11*
31.42 ±
6.18*
0.32 ± 0.01*

4. Discussion
The current work demonstrated the development of ALO as a critical
candidate for ameliorating ROT-induced neurotoxicity, which is strik
ingly similar to PD. Our observations reported for the first time possible
molecular pathways underlying the neuroprotective effect of the DPP-4
enzyme inhibitor, ALO, in the ROT model of PD. Pleiotropic actions of
ALO include at least partly activating AMPK/SIRT1/PGC-1α signaling
pathway, mitigating HMGB1/TLR4/NLRP3 inflammasome activation,
alleviating inflammation, attenuating neuronal damage, and halting the
deleterious effect of ROT.
PD is associated with a plethora of events including, progressive
degeneration of dopaminergic neurons and the consequent exhaustion
of striatal DA content, which results in the cardinal motor manifestations

− 23 ± 12.26*
31.63 ±
1.21*,$
0.98 ± 0.09*,
#

Data represent mean ± SD of 16 rats per group for survival and weight change or
seven rats for striatal DA and GLP-1. The analysis was conducted statistically
utilizing ANOVA accompanied by Tukey's post-hoc test. ROT: rotenone, ALO:
alogliptin, DOR: dorsomorphin, DA: dopamine, GLP-1: glucagon-like peptide 1.
*
P-value less than 0.05 versus control.
#
P-value less than 0.05 versus ROT.
$
P-value less than 0.05 versus ALO.
4
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Fig. 1. Effect of ALO on the locomotion of ROT rats in the open field and rotarod tasks. The panels depict the distance traveled (A), the mean speed (B), the time
spent immobile (C), the rearing incidence (D), example track plots of rats throughout the open field test (E) and rotarod fall off latency (F). n = 12–16 (mean ±
standard deviation). * Versus control, # versus ROT, and $ versus ROT+ALO (ANOVA accompanied by Tukey's post hoc test, except rearing incidence, which was
examined utilizing Kruskal-Wallis test accompanied by Dunn's multiple comparison test; P-value less than 0.05). ROT stands for rotenone, ALO for alogliptin, and
DOR for dorsomorphin.

Fig. 2. ALO's effect on histopathological changes in rats treated with ROT. Characteristic H&E photomicrographs of the striatum (A–D) and SNpc (E–H) from the
control group (A and E), the ROT group (B and F), the ROT+ALO group (C and G), and the ROT+ALO + DOR group (D and H). The black arrows denote intact
neurons, the red arrows denote degraded pyknotic neurons, and the arrowheads denote glial cell invasion. Magnification factor: 400. SNpc stands for substantia nigra
pars compacta; ROT stands for rotenone; ALO stands for alogliptin; DOR stands for dorsomorphin. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)

[2]. In the current study, open field and rotarod tests revealed significant
locomotor impairment in ROT-treated rats. However, ALO administra
tion significantly improved motor performance and muscle coordina
tion. In this context, gliptins have proven efficacy in improving

behavioral and motor abnormalities in the rat model of Huntington's
disease, as well as memory and learning defects in the rat model of
Alzheimer's disease [52,53].
The findings of this work showed that ROT led to a considerable
5
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Fig. 3. ALO's impact on SNpc TH immunoreactivity in ROT rats. Characteristic immunohistochemistry photomicrographs of TH in SNpc from rats treated with ROT
(B), ROT+ALO(C), ROT+ALO + DOR (D), and % area of TH immunoexpression in SNpc slices from the four groups (E). Magnification: x400. n = 3 rats in each group
(mean standard deviation). * Compared to control, # compared to ROT, and $ compared to ROT+ALO (one-way ANOVA accompanied by Tukey's post hoc test; P
0.05). TH stands for tyrosine hydroxylase, SNpc stands for substantia nigra pars compacta, ROT stands for rotenone, ALO stands for alogliptin, and DOR stands for
dorsomorphin.

reduction in weight, which may be attributed to the drug's energy loss
and subsequent metabolic dysfunction, as well as decreased food con
sumption and anorexia linked with motor deficiency [54]. Likewise,
individuals with PD lost significant amounts of weight due to non-motor
problems impacting taste and olfaction, cognition, and mood, all of
which may impact eating behaviors and food processing [55]. Excit
ingly, ALO did not play a role in any greater weight loss compared to the
ROT group; however, it did result in a modest increase in body weight
that was not statistically significant. Additional research demonstrates
that ALO has a weight-neutral impact [56,57]. A similar favorable
weight profile was observed with other DPP-4 inhibitors over GLP-1
analogs, which are correlated with sustained dose-dependent weight
loss [52,58,59]. This weight neutrality impact would support ALO use,
as treating physicians must remain watchful regarding weight loss in
individuals with PD.
ROT therapy resulted in a large depletion of nigrostriatal dopami
nergic neurons, as indicated by an apparent loss of SNpc TH-positive
cells, followed by a considerable decrease in striatal DA levels. More
over, dopaminergic neuronal loss was confirmed with histopathological

examinations, which revealed focal neuronal damage accompanied with
moderate glial cell infiltrates; In the SNpc, there is substantial neuronal
degeneration and loss, as evidenced by numerous images of angular
degraded and pyknotic neurons. Interestingly, the ALO-treated group
showed a marked recovery of SNpc TH and striatal DA contents.
Consistent with these observations, histological examination of ALOtreated rats showed apparent intact well-protected neurons in striatum
and SNpc.
GLP-1 is a possible target for the treatment of PD. GLP-1 appears to
be critical for the correct maintenance and growth of dopaminergic
neurons in the SNpc [60]. Furthermore, numerous studies have shown
that GLP-1 receptor stimulation either by agonist or DPP-4 inhibitor has
neuroprotective effects in PD, which leads to improvements in motor
and non-motor deficits [50,61,62]. However, exact molecular mecha
nisms for GLP-1's effect have not yet been fully tackled. The AMPK/
SIRT1 pathway is documented as a pivotal downstream signaling
pathway for GLP-1. Several studies have shown that GLP-1 induces
AMPK activation, which in turn activates SIRT1 via raising the NAD/
NADH ratio [50,51]. Activated SIRT1 deacetylates PGC-1α, thereby
6
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the AMPK/SIRT1/PGC1-α axis affects PD development [66].
Surprisingly, the present investigation discovered that ROT rats had
a marked reduction in striatal GLP-1 that was coupled by a considerable
decrease in its downstream signaling cascade; pT172-AMPK, SIRT1,
PGC-1α and the key activator of mitochondrial transcription TFAM. The
coexistence of ROT-induced striatal GLP-1 depletion and striatal toxicity
as measured by DA decrease demonstrates the proof for a function for
GLP-1 in PD pathogenesis. Similarly, the correlation between GLP-1 and
altered mitochondrial homeostasis in PD has been widely documented
[37]. Contrariwise, the ALO-treated group showed a marked recovery in
striatal GLP-1, pT172-AMPK, SIRT1, PGC-1α, and TFAM contents. To
ensure that the neuroprotective of ALO is directly related to the previous
alteration in the AMPK/SIRT1/PGC1-α axis, DOR, an AMPK inhibitor
was used. Inactivating AMPK by DOR dramatically prevented ALO's
amendment of those biomarkers. This occurred concurrently with the
histological improvement conferred by ALO on abolishment. DOR also
markedly abated ALO's beneficial effects on mortality, bodyweight
reduction as well as striatal DA depletion. These results suggest that
ALO's neuroprotective effects are mediated through the AMPK/SIRT1/
PGC1-α axis.
The adverse effect of ROT may also result from the elevated levels of
pyroptosis-associated proteins NLRP3, cleaved caspase-1, and IL-1. The
NLRP3 inflammasome has sparked considerable attention in recent
years, and numerous studies have been undertaken to fully understand
the role of NLRP3 in the course of PD [67]. In PD patients, oxidative
stress and pathogenic α-synuclein aggregates stimulate the microglial
NLRP3 inflammasome pathway [68]. It is hypothesized that stimulation
of the NLRP3 inflammasome requires a priming signal and an activation
signal. Priming signals, such as TLR stimulation by DAMPs including
HMGB1, are required for NLRP3 transcription. The second signal,
including sensing α-synuclein, promotes inflammasome complex for
mation and stimulation [49]. Activation of the NLRP3 inflammasome
activates cleaved caspase-1, promotes the maturation of IL-1, and the
production of pyroptosis, which further increases IL-1 secretion, which
plays a vital role in the development of PD [69].
Our findings indicated that ROT rats had increased levels of
inflammasome components NLRP3, cleaved caspase-1, and IL-1. The
activation of the NLRP3 inflammasome could be a result of the syner
gistic effect of HMGB1-induced TLR stimulation and the lack of SIRT1
inhibitory activity on the inflammasome, as indicated by increased
striatal HMGB1 and TLR4 expression and reduced SIRT1 expression.
Additionally, recent research has established that SIRT1 modulates
neuroinflammation by inhibiting the TLR pathway, which rationalizes
SIRT1's inhibitory action on the NLRP3 inflammasome [70]. Addition
ally, excessive microglial activation is shown in rats treated with ROT by
an increased number of Iba1-positive cells. Numerous studies have
demonstrated that activating microglia stimulates the generation of
neurotoxic mediators such as ROS, chemokines, and cytokines, which
directly induce neuroinflammation in the brain [49]. According to these
observations, multiple investigations suggest that ROT-induced PD ac
tivates the microglial NLRP3 inflammasome [71,72].
Surprisingly, ALO protects against the inflammatory pandemonium
generated by ROT, as seen by decreased striatal HMGB1 and TLR4
expression, as well as a concurrent decrease in inflammasome activation
as revealed by lower NLRP3, caspase-1, and IL-1 expression. Indeed,
ALO inhibited microglial activation by restoring the normal population
of Iba1-positive cells. Intriguingly, DOR-mediated inhibition of AMPK/
SIRT1 signaling abolished the majority of the positive benefits of ALO
therapy. The protective effect of ALO may be explained in this setting by
SIRT1-dependent suppression of NLRP3 inflammasome activation.
Anagliptin, a DPP-4 inhibitor, inhibited the NLRP3 inflammasome
activation regulated by SIRT1 [73]. Therefore, DPP-4 inhibitors may
serve as a defense against inflammasome activation.

Fig. 4. ALO's impact on striatal Iba1 immunoreactivity in ROT rats. Immuno
histochemical staining of Iba1 in the striatum of control rats (A), ROT rats (B),
ROT+ALO treated rats (C), and ROT+ALO + DOR-treated rats (D) is shown in
representative photomicrographs. E Iba1 positive cells per field in striatal slices
of the four groups. Magnification: x400. n = 3 rats in each group (mean stan
dard deviation). * Compared to control, # compared to ROT, and $ compared to
ROT+ALO (one-way ANOVA accompanied by Tukey's post hoc test; P 0.05).
Iba1 stands for ionized calcium-binding adaptor molecule 1, ROT stands for
rotenone, ALO stands for alogliptin, and DOR stands for dorsomorphin.

Fig. 5. ALO’s effect on the levels of pT172-AMPK (A), SIRT1 (B), PGC-1α (C),
and TFAM (D) in the striatum. n = 5–7 (mean ± SD) * Compared to control, #
compared to ROT, and $ compared to ROT+ALO (one-way ANOVA accompa
nied by Tukey's post hoc test; P-value less than 0.05). SIRT1; sirtuin 1, PGC-1α;
proliferator-activated receptor gamma coactivator-1 alpha, TFAM; mitochon
drial transcription factor A, ROT; rotenone, ALO; alogliptin, DOR;
dorsomorphin.

promoting mitochondrial biogenesis [25]. This novel observation shows
that AMPK, SIRT1, and PGC-1α may act in conjunction to maintain
metabolic homeostasis [63]. The PGC-1α regulates critical neural
pathways in the brain. Additionally, PGC-1α loss results in significant
hyperactivity associated with striatal axonal degeneration [64]. It is
plausible that PGC-1α has a peculiar role in PD through different sce
narios including, boosting mitochondrial biogenesis, promoting the
antioxidant response, hindering α-synuclein oligomerization and
neurotoxicity [65]. Consistently, there is a lot of evidence indicating that
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Fig. 6. ALO’s effect on striatal HMGB1 (A) and TLR4 (B) mRNA expression, NLRP3 (C) and caspase-1 (D) protein expression, and IL-1β (E) expression. n = 3–7
(mean ± SD) * Compared to control, # compared to ROT, and $ compared to ROT+ALO (one-way ANOVA accompanied by Tukey's post hoc test; P-value less than
0.05). HMGB1 stands for high-mobility group box 1, TLR4 stands for toll-like receptor 4, NLRP3 stands for nucleotide-binding and oligomerization domain (NOD)like receptor pyrin domain-containing 3, IL-1β stands for interleukin 1 beta, ROT stands for rotenone, ALO stands for alogliptin, and DOR stands for dorsomorphin.

5. Conclusions

Declaration of competing interest

Alogliptin, an incretin preserver, increased GLP-1, triggered the
AMPK/SIRT1/PGC-1α signaling pathway, inhibited NLRP3 inflamma
some activation, restored DA levels, reduced neuronal dysfunction, and
enhanced motor quality of the current study. The current study suggests
that medication with the ALO is a highly promising approach for PD. In
conclusion, our findings contribute to future research to elucidate the
neuroprotective mechanisms underlying DPP-4 inhibitors' neuro
protective benefits in PD.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.lfs.2021.120132.

None.
Acknowledgements
The authors thank Prof. Mohamed Abdel Razek, Faculty of Veteri
nary Medicine, Cairo University for conducting histological and immu
nohistochemical evaluation.
References
[1] G.E. Alexander, Biology of Parkinson’s disease: pathogenesis and pathophysiology
of a multisystem neurodegenerative disorder, Dialogues Clin. Neurosci. 6 (2004)
259–280, https://doi.org/10.31887/DCNS.2004.6.3/galexander.
[2] S. Mullin, A.H.V. Schapira, Pathogenic mechanisms of neurodegeneration in
parkinson disease, Neurol. Clin. 33 (2015) 1–17, https://doi.org/10.1016/j.
ncl.2014.09.010.
[3] S. Phani, J.D. Loike, S. Przedborski, Neurodegeneration and inflammation in
Parkinson’s disease, Parkinsonism Relat. Disord. 18 (2012) S207–S209, https://
doi.org/10.1016/S1353-8020(11)70064-5.
[4] P.M. Keeney, J. Xie, R.A. Capaldi, J.P. Bennett, Parkinson’s disease brain
mitochondrial complex I has oxidatively damaged subunits and is functionally
impaired and misassembled, J. Neurosci. 26 (2006) 5256–5264, https://doi.org/
10.1523/JNEUROSCI.0984-06.2006.
[5] W.G. Tatton, R. Chalmers-Redman, D. Brown, N. Tatton, Apoptosis in Parkinson’s
disease: signals for neuronal degradation, Ann. Neurol. 53 (2003) S61–S72,
https://doi.org/10.1002/ana.10489.
[6] J.M. Taylor, B.S. Main, P.J. Crack, Neuroinflammation and oxidative stress: coconspirators in the pathology of Parkinson’s disease, Neurochem. Int. 62 (2013)
803–819, https://doi.org/10.1016/j.neuint.2012.12.016.
[7] L. Rodriguez, M.M. Marano, A. Tandon, Import and export of misfolded
α-synuclein, Front. Neurosci. 12 (2018) 344, https://doi.org/10.3389/
fnins.2018.00344.

Funding
This research was funded by a grant from the British University in
Egypt's Young Investigator Research Program (Grant number:
YIRG2018-08).
CRediT authorship contribution statement
Marwa M. Safar: Conceptualization, Investigation, Resources,
Writing – review & editing. Noha F. Abdelkader: Investigation, Re
sources, Writing – original draft, Writing – review & editing. Eman
Ramadan: Investigation, Writing – original draft. Mona A. Kortam:
Writing – original draft. Ahmed F. Mohamed: Conceptualization,
Investigation, Writing – original draft.

8

Life Sciences 287 (2021) 120132

M.M. Safar et al.
[8] P. Jenner, Wearing off, dyskinesia, and the use of continuous drug delivery in
Parkinson’s disease, Neurol. Clin. 31 (2013) S17–S35, https://doi.org/10.1016/j.
ncl.2013.04.010.
[9] S.-B. Liu, W.-L. Mi, Y.-Q. Wang, Research progress on the NLRP3 inflammasome
and its role in the central nervous system, Neurosci. Bull. 29 (2013) 779–787,
https://doi.org/10.1007/s12264-013-1328-9.
[10] J.A. Holbrook, H.H. Jarosz-Griffiths, E. Caseley, S. Lara-Reyna, J.A. Poulter, C.
H. Williams-Gray, D. Peckham, M.F. McDermott, Neurodegenerative disease and
the NLRP3 inflammasome, Front. Pharmacol. 12 (2021), 643254, https://doi.org/
10.3389/fphar.2021.643254.
[11] F. Martinon, K. Burns, J. Tschopp, The inflammasome: a molecular platform
triggering activation of inflammatory caspases and processing of proIL-β, Mol. Cell
10 (2002) 417–426, https://doi.org/10.1016/S1097-2765(02)00599-3.
[12] M. Haneklaus, L.A. O’Neill, R.C. Coll, Modulatory mechanisms controlling the
NLRP3 inflammasome in inflammation: recent developments, Curr. Opin.
Immunol. 25 (2013) 40–45, https://doi.org/10.1016/j.coi.2012.12.004.
[13] S. Jha, S.Y. Srivastava, W.J. Brickey, H. Iocca, A. Toews, J.P. Morrison, V.S. Chen,
D. Gris, G.K. Matsushima, J.P.-Y. Ting, The inflammasome sensor, NLRP3,
regulates CNS inflammation and demyelination via Caspase-1 and Interleukin-18,
J. Neurosci. 30 (2010) 15811–15820, https://doi.org/10.1523/JNEUROSCI.408810.2010.
[14] J. Thundyil, K.-L. Lim, DAMPs and neurodegeneration, Ageing Res. Rev. 24 (2015)
17–28, https://doi.org/10.1016/j.arr.2014.11.003.
[15] R. Hanamsagar, M.L. Hanke, T. Kielian, Toll-like receptor (TLR) and inflammasome
actions in the central nervous system, Trends Immunol. 33 (2012) 333–342,
https://doi.org/10.1016/j.it.2012.03.001.
[16] M.G. Frank, M.D. Weber, L.K. Fonken, S.A. Hershman, L.R. Watkins, S.F. Maier,
The redox state of the alarmin HMGB1 is a pivotal factor in neuroinflammatory and
microglial priming: a role for the NLRP3 inflammasome, Brain Behav. Immun. 55
(2016) 215–224, https://doi.org/10.1016/j.bbi.2015.10.009.
[17] R. Velagapudi, A. El-Bakoush, I. Lepiarz, F. Ogunrinade, O.A. Olajide, AMPK and
SIRT1 activation contribute to inhibition of neuroinflammation by thymoquinone
in BV2 microglia, Mol. Cell. Biochem. 435 (2017) 149–162, https://doi.org/
10.1007/s11010-017-3064-3.
[18] H. Yang, W. Zhang, H. Pan, H.G. Feldser, E. Lainez, C. Miller, S. Leung, Z. Zhong,
H. Zhao, S. Sweitzer, T. Considine, T. Riera, V. Suri, B. White, J.L. Ellis, G.
P. Vlasuk, C. Loh, SIRT1 activators suppress inflammatory responses through
promotion of p65 deacetylation and inhibition of NF-κB activity, PLoS One 7
(2012), e46364, https://doi.org/10.1371/journal.pone.0046364.
[19] Y. Li, P. Wang, X. Yang, W. Wang, J. Zhang, Y. He, W. Zhang, T. Jing, B. Wang,
R. Lin, SIRT1 inhibits inflammatory response partly through regulation of NLRP3
inflammasome in vascular endothelial cells, Mol. Immunol. 77 (2016) 148–156,
https://doi.org/10.1016/j.molimm.2016.07.018.
[20] I.H. Lee, L. Cao, R. Mostoslavsky, D.B. Lombard, J. Liu, N.E. Bruns, M. Tsokos, F.
W. Alt, T. Finkel, A role for the NAD-dependent deacetylase Sirt1 in the regulation
of autophagy, Proc. Natl. Acad. Sci. 105 (2008) 3374–3379, https://doi.org/
10.1073/pnas.0712145105.
[21] Y. Wu, X. Li, J.X. Zhu, W. Xie, W. Le, Z. Fan, J. Jankovic, T. Pan, Resveratrolactivated AMPK/SIRT1/Autophagy in cellular models of Parkinson’s disease,
Neurosignals 19 (2011) 163–174, https://doi.org/10.1159/000328516.
[22] M. Xilouri, O.R. Brekk, L. Stefanis, Autophagy and alpha-synuclein: relevance to
Parkinson’s disease and related synucleopathies, Mov. Disord. 31 (2016) 178–192,
https://doi.org/10.1002/mds.26477.
[23] T. Pan, P. Rawal, Y. Wu, W. Xie, J. Jankovic, W. Le, Rapamycin protects against
rotenone-induced apoptosis through autophagy induction, Neuroscience 164
(2009) 541–551, https://doi.org/10.1016/j.neuroscience.2009.08.014.
[24] Y.-S. Hou, J.-J. Guan, H.-D. Xu, F. Wu, R. Sheng, Z.-H. Qin, Sestrin2 protects
dopaminergic cells against rotenone toxicity through AMPK-dependent autophagy
activation, Mol. Cell. Biol. 35 (2015) 2740–2751, https://doi.org/10.1128/
MCB.00285-15.
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